Impact of Patient Age on Biochemical Recurrence Rates Following Radical Prostatectomy

Journal of Urology

Volumn 178, Issue 5, 2007, Pages 1933-1938

  Magheli, Ahmed ^a,b   Rais Bahrami, Soroush ^a   Humphreys, Elizabeth B ^c   Peck, Hugh J ^a   Trock, Bruce J ^a   Gonzalgo, Mark L ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c NONE

Author keywords

age groups; local; neoplasm recurrence; prognosis; prostate; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; FOLLOW UP; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RACE DIFFERENCE; STATISTICAL ANALYSIS;

ADENOCARCINOMA; AGE FACTORS; AGED; BIOPSY; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE PERIOD; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 35148884625     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.07.016     Document Type: Article

References (20)

1. Ung J.O., Richie J.P., Chen M.H., Renshaw A.A., and D'Amico A.V. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 60 (2002) 458
2. Khan M.A., Han M., Partin A.W., Epstein J.I., and Walsh P.C. Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology 62 (2003) 86
3. Smith C.V., Bauer J.J., Connelly R.R., Seay T., Kane C., Foley J., et al. Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database. J Urol 164 (2000) 1964
4. Carter H.B., Epstein J.I., and Partin A.W. Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urology 53 (1999) 126
5. Freedland S.J., Presti Jr. J.C., Kane C.J., Aronson W.J., Terris M.K., Dorey F., et al. Do younger men have better biochemical outcomes after radical prostatectomy?. Urology 63 (2004) 518
6. Freedland S.J., Presti Jr. J.C., Amling C.L., Kane C.J., Aronson W.J., Dorey F., et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology 61 (2003) 736
7. Rubin D.B. On principles for modeling propensity scores in medical research. Pharmacoepidemiol Drug Saf 13 (2004) 855
8. Rubin D.B., and Thomas N. Matching using estimated propensity scores: relating theory to practice. Biometrics 52 (1996) 249
9. Cooner W.H., Mosley B.R., Rutherford Jr. C.L., Beard J.H., Pond H.S., Bass Jr. R.B., et al. Clinical application of transrectal ultrasonography and prostate specific antigen in the search for prostate cancer. J Urol 139 (1988) 758
10. Catalona W.J., Smith D.S., Ratliff T.L., Dodds K.M., Coplen D.E., Yuan J.J., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324 (1991) 1156
11. Catalona W.J., Smith D.S., Ratliff T.L., and Basler J.W. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270 (1993) 948
12. Newcomer L.M., Stanford J.L., Blumenstein B.A., and Brawer M.K. Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994. J Urol 158 (1997) 1427
13. Hankey B.F., Feuer E.J., Clegg L.X., Hayes R.B., Legler J.M., Prorok P.C., et al. Cancer surveillance series: interpreting trends in prostate cancer-part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 91 (1999) 1017
14. Tjaden H.B., Culp D.A., and Flocks R.H. Clinical adenocarcinoma of the prostate in patients under 50 years of age. J Urol 93 (1965) 618
15. Johnson D.E., Lanieri Jr. J.P., and Ayala A.G. Prostatic adenocarcinoma occurring in men under 50 years of age. J Surg Oncol 4 (1972) 207
16. Rosenbaum P.R., and Rubin D.B. The bias due to incomplete matching. Biometrics 41 (1985) 103
17. Siddiqui S.A., Sengupta S., Slezak J.M., Bergstralh E.J., Leibovich B.C., Myers R.P., et al. Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer. J Urol 175 (2006) 952
18. Ruska K.M., Partin A.W., Epstein J.I., and Kahane H. Adenocarcinoma of the prostate in men younger than 40 years of age: diagnosis and treatment with emphasis on radical prostatectomy findings. Urology 53 (1999) 1179
19. Freedman G.M., Hanlon A.L., Lee W.R., and Hanks G.E. Young patients with prostate cancer have an outcome justifying their treatment with external beam radiation. Int J Radiat Oncol Biol Phys 35 (1996) 243
20. Twiss C., Slova D., and Lepor H. Outcomes for men younger than 50 years undergoing radical prostatectomy. Urology 66 (2005) 141